• Rimal H Mousa, Jamal M Melhem, and Eman A Hammad.
• From the Department of Biopharmaceutics and Clinical Pharmacy (Mousa, Hammad); and from the Department of General Surgery (Melhem), Faculty of Medicine-University of Jordan, Amman, Jordan.
• Saudi Med J. 2021 Jul 1; 42 (7): 776-783.

ObjectivesTo evaluate the epidemiology, prognostic factors, and 5-year overall survival (OS) of females with breast cancer (BC) diagnosed between 2011 and 2014 in Jordan.MethodsA retrospective medical review of females who were diagnosed with BC between 2011 and 2014 at the 2 leading public health providers in Jordan was performed. The endpoint of the study was 2018. Data were extracted from the medical files between 2011 and 2018, including demographic clinical data on the patient level. Survival by age, laterality, grade, stage, and treatments modes were calculated by the Kaplan Meier method.ResultsA total of 877 women were included with median age of 51 years and follow-up duration of 2.4 years. Majority of the patients had ductal carcinoma and estrogen receptor (ER) positive type. The 5-year OS for patients with stage I, II, III, and IV, 94%, 86%, and 46% (p<0.001), respectively. The tumor stage and nodal status were the main prognostic variables affecting the overall survival.ConclusionThe incidence in Jordan is increasing, yet survival rates are improving with increased diagnosis during early stages. Therefore, strategies for implementing universal screening programs are advocated to improve clinical outcomes and to reduce the disease burden.Copyright: © Saudi Medical Journal.

21 keywords...

hide…